Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders ...

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal ...

Researchers sought to determine whether patients with T-ALL would be responsive to salvage therapy with homoharringtonine, cytarabine, and aclarubicin.

TCR diversity is critical to fighting infections ... production of recombinant proteins with BioProtein Technologies and gene therapy programs at bluebird bio both in France and in the USA.

View Full Profile. Learn about our Editorial Policies. How can TCR-based therapeutics address the current limitations of treating solid tumors? The TCR increases the number and types of proteins ...

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology. The US regulator ...

One asset, dubbed ADP-600, is designed to target indications that express PRAME—a protein coding gene—such as synovial ... a MAGE-4A TCR T-cell therapy. However, enrollment in two clinical ...